摘要
1商品名 Xolair 2开发与上市厂商 由Genentech、诺华和Tanox公司联合开发，2003年6月20日获美国FDA许可，2003年7月7日首次在美国上市。
出处
《世界临床药物》
CAS
2005年第1期59-59,共1页
World Clinical Drug
同被引文献29
-
1SHANKAR G, PENDLEY C ,STEIN KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs [ J ]. Nat Biotechnol,2007,25 ( 5 ) :555 - 561.
-
2MAGGON K. Global Biotechnology Market Review & World Top Ten Bioteeh Drugs 2008[R/OL]. [ 2009-05 -28]. [2009- 08 - 20 ]. http ://knol. google. com/k/krishan-maggon/global-biotechnology-market-review/3fy5eowy8suq3/ 16.9 version = 62#.
-
3PhRMA. New report on 633 biotechnology medicines under development released in Michigan[ EB/OL]. [2008 -09 -24]. [2008 - 11 - 15 ]. http ://www. phrma. org/news_room/press_releases/new_report_on_633_biotechnology_medicines_under_development/.
-
4UNAIDS. Report on the global AIDS epidemic[ R/OL]. [2008 - 07 - 29 ]. http://www.unaids. org/en/ Knowledge Centre/HIV- Data/ GlobalReport/2008 / default. asp.
-
5FAUCI S. the Release of New Data from the HVTN 502 (STEP) HIV Vaccine Study[ EB/OL]. [2007 - 11 -07 ]. [2009 - 05 - 05]. http://www3. niaid.nih. gov/about/directors/news/step _11707. htm.
-
6SERONO,INC. Serostim receives full FDA approval for treatment of AIDS wasting[ EB/OL]. [ 2003 - 08 - 29 ]. [ 2009 - 05 - 12 ]. http://www.drugs. com/news/serostim-receives-full-fdaapproval-aids-wasting-3376. html.
-
7PAZDUR R. FDA Approval for Romiplostim[ EB/OL]. [ 2009 - 05 - 15 ]. http://www. cancer. gov/ cancertopics/druginfo/fda - romiplostim/print? page = &keyword =.
-
8CENTOCOR ORTHO BIOTECH INC. SimponiTM (golimumab) receives fda approval as first once - monthly anti-tnf for treatment of rheumatoid arthritis,psoriatic arthritis and ankylosingspondylitis [EB/OL ] [2009 -04 -24]. [2009 -05 -20]. http:// centocororthobiotech, com/cobi/viewDocumentByTitleAlias. html? title = PR_SIMPONI_US_APPROVAL.
-
9UCB' s Cimzia (certolizumab pegol) approved by the U. S. FDA for adult patients suffering from moderate to severe rheumatoid arthritis[ EB/OL]. [2009 - 05 - 14 ]. [ 2009 - 05 - 20 ]. http:// www. ucb. com/news/newsdetail/? det = 1314787.
-
10NAGAYAMA O. Actemra ,a humanized anti-human il-6 receptor monoclonal antibody obtained approval for indications of rheumatoid arthritis,polyarticular-course juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis [ EB/OL]. [ 2008 - 04 - 16]. [ 2009 - 05 - 20 ]. http://www. chugai - pharm. co. jp/ MEDIA/mediaRepository /6300004/080416eAct. pdf.
二级引证文献2
-
1杜海洲,王天津,刘桂玲,刘娜,吕婷.医药卫生信息资源整合与集成的开放存取服务平台[J].预防医学情报杂志,2010,26(11):895-899. 被引量：3
-
2司书毅,姜威,白硕可.微生物药物研究进展与发展趋势[J].中国医药生物技术,2011,6(2):81-83. 被引量：2
-
1哮喘治疗药omalizumab[J].中国医药技术与市场,2007,7(4):54-55.
-
2Omalizumab对过敏性哮喘和过敏性鼻炎的作用[J].国外新药介绍,2002(1):22-25.
-
3卢作勇.Omalizumab治疗哮喘和鼻炎新药[J].中国制药信息,2001,17(9):26-27.
-
4omalizumab可用作哮喘控制不佳的辅助治疗[J].世界临床药物,2004,25(9):516-516.
-
5张美珍,王会英.06058 Novartis的Xolair治疗哮喘有效[J].国外药讯,2001(6):29-29.
-
6薛新汶,王保烈.小儿肝损伤的非手术治疗[J].小儿急救医学,2003,10(4):261-261. 被引量：1
-
7何清,曾群英,麦炜颐,廖晓星,李玉杰.缬沙坦治疗轻中度原发性高血压的临床研究[J].国外医学（心血管疾病分册）,2000,27(6):353-355. 被引量：25
-
8王庆茹.缬沙坦治疗原发性高血压65例疗效观察[J].锦州医学院学报,2001,22(6):28-29.
-
9张燕.缬沙坦逆转高血压左室肥厚的临床观察[J].临床荟萃,2001,16(23).
-
10secukinumab治疗强直性脊柱炎[J].临床合理用药杂志,2015,8(20):181-181.
